---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-036112"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:19:37.703980+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs

## Summary
- Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.
- Net loss $9.0M ($0.80/sh) vs $10.8M ($0.96) in Q1 2022; R&D $5.1M, G&A $4.6M.
- Positive preliminary data: TARA-002 well tolerated; tumor regression in all 3 evaluable CIS patients, including a CR in a BCG-unresponsive patient.
- ADVANCED-2 Phase 1b/2 trial in up to 102 CIS patients planned for 2H23; STARBORN-1 Phase 2 in pediatric LMs cleared by FDA, start Q4 2023.
- IV Choline Chloride IFALD prospective study ongoing; results expected Q3 2023, then regulatory feedback.

## SEC filing metadata
- accession: 0001213900-23-036112
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/ea177795-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-036112
- JSON: https://secwatch.observer/filing/0001213900-23-036112.json
- Plain text: https://secwatch.observer/filing/0001213900-23-036112.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income a net loss of $9.0 million, EPS $0.80 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: a net loss of $9.0 million
  - EPS: $0.80 per share
  - Result: reported results
  source text: For the first quarter of 2023, Protara reported a net loss of $9.0 million, or $0.80 per share, compared with a net loss of $10.8 million, or $0.96 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.